文献速递肿瘤 PET/CT

18F-FDG-PET在黑色素瘤患者治疗开始两周后检测PD1治疗的完全缓解

18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-08-22

研究评估18F-FDG-PET能否在不可切除转移性黑色素瘤患者启动PD1治疗两周后识别完全缓解者。2014年9月至2016年5月纳入10例患者,在基线、两周和研究参考标准三个月时行全身18F-FDG-PET/MRI,采用PERCIST评估疗效。结果显示两周时部分代谢缓解的3例患者在三个月时达到完全缓解,至今未观察到肿瘤复发。

要点

  • 10例不可切除转移性黑色素瘤患者在PD1治疗前、治疗两周和三个月时行全身18F-FDG-PET/MRI。
  • 两周时部分代谢缓解的3例患者在三个月时均达到完全缓解,观察期内未见肿瘤复发。
  • 研究提示全身18F-FDG-PET可能在治疗开始两周后可靠识别完全缓解者。

核心结论

  • 研究提示全身18F-FDG-PET可能在IV期黑色素瘤患者PD1治疗开始两周后可靠识别完全缓解者,未来可能有助于缩短治疗方案并避免不必要的副作用。

研究设计与样本

  • 2014年9月至2016年5月纳入10例患者(4例女性;65 ± 12岁),在治疗开始前(t0,基线)、两周(t1,研究检查)和治疗开始三个月后(t2,参考标准)行全身18F-FDG-PET/MRI检查。
  • 采用实体瘤PET疗效标准(PERCIST)评估治疗反应,并获取所有患者的进展时间和总生存期(OS)。

主要发现

  • t1时PET显示部分代谢缓解的3例患者在t2时达到完全缓解,观察期分别为265天、511天和728天,至今未观察到肿瘤复发。
  • t2时6例患者出现进展性代谢疾病(PMD),其中4例在t1时已显示PMD,2例在t1时显示稳定代谢疾病(SMD)。
  • t2时PMD患者的总生存期在148天至814天之间。
  • 1例患者在t1和t2时均显示SMD,308天后观察到肿瘤进展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of the study was to evaluate if 18F-FDG-PET has the potential to detect complete responders to PD1-therapy in patients with unresectable metastasized melanoma two weeks after therapy initiation. METHODS: Between September 2014 and May 2016, ten patients (four females; 65 ± 12 y) received a whole-body 18F-FDG-PET/MRI examination at three time points: Before therapy start (t0, base-line), two weeks (t1, study examination) and three months after treatment initiation (t2, reference standard). Therapy response was assessed with PET response criteria in solid tumors (PERCIST). Time to progression and overall survival (OS) were obtained for all patients. RESULTS: Three patients with partial metabolic response in PET at t1 turned out to have complete response at t2. No tumor relapse was observed in those patients so far (observation period: 265, 511 and 728 days, respectively). At t2, progressive metabolic disease (PMD) was seen in six patients from whom four showed PMD and two showed stable metabolic disease (SMD) at t1. OS in patients with PMD at t2 varied between 148 and 814 days. SMD at both t1 and t2 was seen in one patient, tumor progress was observed after 308 days. CONCLUSION: Our study indicates that whole-body 18F-FDG-PET might be able to reliably identify complete responders to PD1-therapy as early as two weeks after therapy initiation in stage IV melanoma patients. This might help to shorten therapy regimes and avoid unnecessary side effects in the future.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Seith F, Forschner A, Schmidt H, et al. 18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start. Eur J Nucl Med Mol Imaging. 2017. PMID: 28831583. doi:10.1007/s00259-017-3813-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。